Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRC105 and Pazopanib in Advanced Angiosarcoma
NCT02979899Phase 3Completed
- Sponsor
- TRACON Pharmaceuticals, Inc.
- Start
- Feb 2017
- Primary completion
- Apr 2019
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of carotuximab in angiosarcoma (2 arms), sponsored by TRACON Pharmaceuticals, Inc. Primary endpoint: Progression Free Survival at 25 months. Started Feb 2017; status: completed.
02
Drugs
carotuximab
03
Conditions
angiosarcoma
Beyond the preview
Go deeper on NCT02979899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02979899.